3rd Jun 2025 22:11
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:
----------
Hemogenyx Pharmaceuticals PLC - London-headquartered biopharmaceutical company focused on treatments for blood diseases - raises GBP451,250 via an allotment to Chief Executive Vladislav Sandler of 250,000 shares at 180.50 pence each. Proceeds will help continue phase I clinical trials for the company's Chimeric Antigen Receptor T-cell therapy, aimed at treating relapsed/refractory acute myeloid leukemia in adults. Following allotment of the new shares, Sandler agrees to sell them to an institution, who will sell the shares at the same issue price to a purchaser identified by it. Sandler says: "We are pleased to have secured funding from a committed investor at a premium to the prevailing market price - an indication of their confidence in the long-term potential of Hemogenyx and our HG-CT-1 program. This support enables us to continue advancing our phase I clinical trial without undue dilution and at a pivotal moment in the development of our therapy for relapsed/refractory AML." Further, announces that the second patient has been successfully treated in the ongoing phase I clinical trial of HG-CT-1. Says the treatment was well tolerated and met the trial's predefined initial safety criteria. Encouragingly, early indications of clinical efficacy are evident, firm says. The patient will continue to be monitored according to the FDA-approved trial protocol to assess whether the study's secondary endpoints are achieved.
----------
Valereum PLC - focused on tokenised digital markets as an exchange and marketplace operator - announces a USD2.5 million strategic investment in Blubird Global Inc, for a minority stake. The investment will be made in eight tranches. Valereum expects to complete the acquisition of the first tranche in June, with the remaining tranches expected to be completed by September. Blubird, a Delaware-based software-as-a-service business, provides mission-critical tools to Web3 startups, as well as traditional Web2 companies migrating to Web3's blockchain technology, with the aim of innovating and disrupting traditional markets. "Blubird have an impressive suite of tools and are already partnered up with leaders like Sony via the Soneium project and Redbelly Network. This investment is designed to speed up innovation and open opportunities for both companies to push forwards in real-world asset tokenisation," company says. In addition, raises GBP500,000 via a placing by Fortified Securities at an issue price of 4 pence per share. Fortified Securities will become Valereum's broker and represent the company with immediate effect. In addition, company agrees to issue 625,000 new news shares in lieu of the cash fees payable to Fortified and to issue warrants for over 2.0 million shares at a price of 4p per share for a period of 3 years.
----------
URU Metals Ltd - mineral exploration & development company - says an independent 3-D inversion of high-resolution aeromagnetic and airborne gravity data has delineated four drill targets at the Zeb nickel project in South Africa's Limpopo Province. These were four coherent bodies concealed beneath Transvaal dolomite or within the known Uitloop intrusion, Uru says. Targets 1 and 2 are high-priority with "large, coincident gravity-magnetic anomalies directly beneath parallel lobes of the Uitloop chonolith, interpreted as feeder conduits where massive sulphides could pond". Uru adds that modelling indicates dense zones from around 100 metres to over 800 metres below the surface, "significantly deeper than historic drilling, underscoring the untested potential at depth". Comments: "These highlights confirm that multiple dense, magnetically susceptible bodies lie wholly within the company's licence...Importantly, the new modelling expands the search footprint, both laterally and to depths well beyond historic drilling, and delivers a suite of clearly defined, drill-ready targets. Together, these factors give the company a compelling, capital-efficient path to massive sulphide discovery, rapid resource definition and near-term value creation for shareholders."
----------
Artemis Resources Ltd - gold, copper and lithium focused mining company with projects in Western Australia - outlines a substantial drill program of up to 5,000m including extensional drilling and technical studies at the Carlow Gold and Copper Project, RC drilling at Titan, and exploration at Cassowary. At Carlow Gold, says diamond drilling will test the potential for significant extensions to the Carlow high-grade gold and copper lode system, well beyond the current limit of drilling. At Titan, says targets are for an infill gravity survey to confirm 4 gravity anomalies and for RC drilling to test the G1 anomaly. At Cassowary, says the Artemis EL application covering the large Cassowary Intrusion is expected to be granted in September quarter. Managing Director Julian Hanna comments: "The next few months should be an exciting period for Artemis with drill programs aimed at growing the scale of the Carlow Project and technical studies required to move Carlow towards possible feasibility and early development stages. The first priority is widely spaced diamond drilling to scope out potential for significant extensions to the high-grade gold and copper lodes along strike and below the mineral resource announced in October 2022, and to provide core samples for metallurgical test work."
----------
Renalytix PLC - London-based diagnostics company - announces a collaboration with New York Kidney & Hypertension Medicine to expand access to kidneyintelX.dkd, the FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in patients with type 2 diabetes and chronic kidney disease stages 1-3b. The collaboration will expand the use of kidneyintelX.dkd blood testing in underserved, high-risk communities to mitigate progressive decline in kidney function and help preserve patient health and quality of life. Renalytix expects the program to enable access to over 2,000 patients for kidneyintelX.dkd prognostic blood testing, complementing Renalytix expanded access programs throughout the Northeast region.
----------
By Jeremy Cutler, Alliance News reporter
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
HemogenyxUru MetalsArtemis ResRenalytix Plc